Karyopharm Therapeutics Ownership | Who Owns Karyopharm Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Karyopharm Therapeutics Ownership Summary


Karyopharm Therapeutics is owned by 58.49% institutional investors, 6.04% insiders, and 35.47% retail investors. Vanguard group is the largest institutional shareholder, holding 6.63% of KPTI shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.73% of its assets in Karyopharm Therapeutics shares.

KPTI Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockKaryopharm Therapeutics58.49%6.04%35.47%
SectorHealthcare Stocks 47.06%8.01%44.93%
IndustryBiotech Stocks 44.97%7.82%47.21%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Vanguard group7.65M6.63%$6.64M
Palo alto investors lp5.10M4.42%$4.43M
Eversept partners, lp4.99M4.32%$4.33M
Adage capital partners gp4.32M3.74%$3.75M
Blackrock4.17M3.61%$3.62M
Marshall wace, llp2.58M2.24%$2.25M
Goldman sachs group2.29M1.98%$1.99M
Bnp paribas arbitrage, snc2.27M1.97%$1.97M
Millennium management2.09M1.81%$1.82M
Avidity partners management lp2.02M1.75%$1.75M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Alphacentric advisors1.13M0.72%$976.05K
Palo alto investors lp5.10M0.51%$4.43M
Birchview capital, lp469.83K0.38%$407.63K
Eversept partners, lp4.99M0.30%$4.33M
Altium capital management lp740.00K0.26%$642.02K
Silverarc capital management558.47K0.11%$484.52K
Avidity partners management lp2.02M0.07%$1.75M
Ikarian capital409.36K0.06%$355.16K
Gsa capital partners llp983.42K0.06%$853.00K
Dafna capital management192.68K0.04%$167.17K

Top Buyers

HolderShares% AssetsChange
Jane street group1.55M0.00%1.38M
Kennedy capital management1.20M0.02%1.20M
Millennium management2.09M0.00%906.55K
Adage capital partners gp4.32M0.01%819.84K
Goldman sachs group2.29M0.00%782.17K

Top Sellers

HolderShares% AssetsChange
Avidity partners management lp2.02M0.07%-6.28M
Blackrock4.17M0.00%-5.28M
State street453.81K--1.83M
Opaleye management---1.43M
Geode capital management1.31M0.00%-1.21M

New Positions

HolderShares% AssetsChangeValue
Kennedy capital management1.20M0.02%1.20M$1.04M
Point72 asia (singapore) pte.165.32K0.03%165.32K$143.43K
Qube research106.47K0.00%106.47K$92.37K
Victory capital management13.99K-13.99K$12.14K
Blb&b advisors11.15K0.00%11.15K$9.67K

Sold Out

HolderChange
Zurcher kantonalbank (zurich cantonalbank)-6.00
Farther finance advisors-13.00
Nelson, van denburg & campbell wealth management group-22.00
Nisa investment advisors-50.00
Financial gravity asset management-50.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2024120-67,526,761-9.69%581.36%53-7.02%336.45%
Mar 31, 2024120-3.23%74,774,7681.78%651.59%5718.75%31-24.39%
Dec 31, 2023124-1.59%73,464,527-4.85%641.41%48-14.29%4136.67%
Sep 30, 2023126-12.50%77,205,610-5.32%671.31%56-24.32%30-28.57%
Jun 30, 20231445.88%81,541,549-6.87%711.21%74-4240.00%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv3.42M2.73%-
Vanguard Explorer Inv2.01M1.61%-
Vanguard Institutional Extnd Mkt Idx Tr1.64M1.32%-
C WorldWide Healthcare Select 1A1.50M1.20%-
AlphaCentric LifeSci Healthcare I1.13M0.90%-
AlphaCentric Life Sciences & Hlthcare I1.13M0.90%-
Kennedy Micro Cap1.05M0.84%-13.30K
Fidelity Extended Market Index723.24K0.58%41.59K
Xtrackers MSCI World Swap ETF 1C712.70K0.57%-
BlackRock Advantage Small Cap Core Instl702.01K0.56%-

Recent Insider Transactions


DateNameRoleActivityValue
Nov 05, 2024Paulson Richard A. President and CEOSell$3.35K
Oct 04, 2024Paulson Richard A. President and CEOSell$3.17K
Sep 04, 2024Mano Michael SVP, General Counsel&SecretarySell$2.87K
Sep 04, 2024Paulson Richard A. President and CEOSell$2.65K
Sep 04, 2024Mason Michael EVP, CFO & TreasurerSell$5.09K

Insider Transactions Trends


DateBuySell
2024 Q4-2
2024 Q3-7
2024 Q2-16
2024 Q1-19
2023 Q4-3

KPTI Ownership FAQ


Who Owns Karyopharm Therapeutics?

Karyopharm Therapeutics shareholders are primarily institutional investors at 58.49%, followed by 6.04% insiders and 35.47% retail investors. The average institutional ownership in Karyopharm Therapeutics's industry, Biotech Stocks , is 44.97%, which Karyopharm Therapeutics exceeds.

Who owns the most shares of Karyopharm Therapeutics?

Karyopharm Therapeutics’s largest shareholders are Vanguard group (7.65M shares, 6.63%), Palo alto investors lp (5.1M shares, 4.42%), and Eversept partners, lp (4.99M shares, 4.32%). Together, they hold 15.37% of Karyopharm Therapeutics’s total shares outstanding.

Does Blackrock own Karyopharm Therapeutics?

Yes, BlackRock owns 3.61% of Karyopharm Therapeutics, totaling 4.17M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 3.62M$. In the last quarter, BlackRock decreased its holdings by -5.278M shares, a -55.86% change.

Who is Karyopharm Therapeutics’s biggest shareholder by percentage of total assets invested?

Alphacentric advisors is Karyopharm Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.72% of its assets in 1.12M Karyopharm Therapeutics shares, valued at 976.05K$.

Who is the top mutual fund holder of Karyopharm Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Karyopharm Therapeutics shares, with 2.73% of its total shares outstanding invested in 3.42M Karyopharm Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools